Related Experiment Video
Updated: Dec 28, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
10.0K
Evolving therapies for lower-risk myelodysplastic syndromes
Jan Philipp Bewersdorf1, Amer M Zeidan2
1Department of Medicine, Section of Hematology, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT, 06520-8028, USA.
Annals of Hematology
|February 21, 2020
Summary
Therapeutic options for myelodysplastic syndromes (MDS) are advancing. Personalized treatments incorporating genetic insights and novel agents like luspatercept show promise for managing symptomatic anemia in lower-risk MDS.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Therapeutic progress for myelodysplastic syndromes (MDS) has historically lagged, with no new drug approvals for 13 years.
- Current MDS treatment relies on risk stratification tools like IPSS and IPSS-R.
- Recent advancements have significantly improved understanding of MDS molecular pathogenesis and genetic landscape.
Purpose of the Study:
- To review current treatments for lower-risk MDS.
- To discuss emerging therapies for symptomatic anemia in lower-risk MDS.
- To explore the impact of genetic mutational analysis on individualized MDS management.
Main Methods:
- Literature review of current MDS treatments.
- Review of clinical trial data for novel MDS agents.
- Discussion of genetic biomarkers and their role in MDS management.
Main Results:
- Luspatercept and imetelstat are promising agents in clinical testing for symptomatic anemia in lower-risk MDS.
- Individualized treatment approaches based on genetic features are expected to become standard.
- Wider availability of mutational analysis will inform personalized MDS patient management.
Conclusions:
- The therapeutic landscape for MDS is evolving towards personalized medicine.
- Novel agents and genetic profiling are key to improving outcomes for MDS patients.
- Future MDS management will integrate molecular data for tailored treatment strategies.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
3.8K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.8K
01:22Bone Marrow Sampling and Transplants
748
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
748
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:22iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K